Buy the Dip: Lilly's GLP-1 Engine Still Driving Growth — A 180-Day Trade
Eli Lilly's cardiometabolic franchise continues to dominate industry headlines and company sales. The stock has pulled back from highs but fundamentals and technicals suggest the recent dip is a buying opportunity for a measured 180-day trade. Trade plan, rationale, catalysts, and balanced risks provided.